Background
==========

Cutaneous squamous cell carcinoma (SCC) and malignant melanoma (CMM) are among the most prevalent \[[@B1]\] and rapidly increasing malignancies in white populations worldwide \[[@B2]\]. In Norway, the incidence of these cancers has increased sevenfold during the last fifty years. In 2010, SCC and CMM represented more than 10% of all new cancer cases in Norway \[[@B3]\]. The major environmental risk factor for all skin cancers is ultraviolet radiation (UVR) from sunlight; consequently, there is a distinct north--south gradient in skin cancer risk \[[@B4]\]. The type of UVR exposure (e.g. intermittent versus accumulated) appears to differ for SCC and CMM \[[@B5]\]. In addition, individual characteristics such as skin type, eye and hair color, nevi and immune suppression are important predictors of individual susceptibility to skin cancer \[[@B6],[@B7]\]. High socioeconomic status is also associated with CMM \[[@B8]\].

SCC is a highly curable disease, and the most recent five-year relative survival rates in Norway are 89% and 93% for men and women respectively \[[@B3]\]. Although CMM carries a higher mortality rate, the 5-year survival rate is still high (77% and 89% for men and women, respectively) \[[@B3]\], due to early diagnosis and successful treatment. During the last fifteen years, several studies have suggested that a history of skin cancer increases the risk for a new primary cancer, both of the skin and other sites \[[@B9]-[@B30]\]. Many of these studies were based on cancer registry data, with high quality case ascertainment but lacking data on individual risk factors that might explain this. Other studies have benefitted from individual exposure data collected using questionnaires, but these tended to be smaller and have less rigorous confirmation of skin and subsequent cancers. A reduced risk of new malignancies after skin cancer has also been reported for some cancer sites \[[@B31]-[@B37]\], which some argue is due to the potentially protective effect of high levels of vitamin D that result from UVR exposure \[[@B38]\].

From the Nordic countries, Sweden, Finland and Denmark have reported their risks of second cancers after skin cancer \[[@B12]-[@B14],[@B18],[@B28],[@B29]\], whereas Norway has not previously reported on these risks. Therefore, we used the Norwegian Cancer Registry data to describe the risk of a new primary cancer following SCC or CMM, and to further assess whether sociodemographic factors or cancer family history were associated with risk of subsequent cancers after skin cancer. Identifying those at greatest risk for subsequent cancers may benefit future public health initiatives by targeting interventions appropriately in the prevention and/or early detection of subsequent malignancies.

Methods
=======

Study population
----------------

Our study cohort included all persons with a histologically verified invasive cutaneous malignant melanoma (N = 28 069) or squamous cell carcinoma (N = 24 620) diagnosed as a first primary cancer in the period 1955--2008 (Table  [1](#T1){ref-type="table"}). The *Cancer Registry of Norway* has registered all cancer diagnoses nationwide from 1953 onwards (not including basal cell carcinoma of skin). Mandatory reporting from multiple independent sources ensures the collection of complete and high quality data \[[@B39]\]. Available information includes date and type of primary skin cancer diagnosis, stage, and anatomical location (head/neck, trunk, arm, leg/foot or other sites) as well as similar data on subsequent cancers. To distinguish new primary cancers from recurrences, the Cancer Registry uses histological information and medical record review; if the histology reports are similar, at least four months must have passed since the initial cancer diagnosis for a later case to be defined as a new primary cancer and clinical records must be consistent with a new primary according to the cancer registry standard \[[@B39]\].

###### 

Descriptive features of the cohort of persons with a first primary cutaneous malignant melanoma (CMM) or squamous cell carcinoma (SCC) at time of the primary skin cancer diagnosis

                                       **CMM**   **SCC**                                           
  ----------------------------------- --------- --------- -------- ------ -------- ------ -------- ------
  **Age at 1**^**st**^**diagnosis**                                                                   
  20-40                                 3249      21.5      1943    15.0    248     2.3     270     2.0
  40-59                                 5435      35.9      4908    38.0    1201    11.0    1492    10.9
  ≥ 60                                  6452      42.6      6082    47.0    9474    86.7   11 935   87.1
  **Age (median)**                      55.6                57.4            75.4            73.2      
  **Anatomical site**                                                                                 
  Head/neck                             2148      14.2      2025    15.7    6560    60.0    8809    64.3
  Trunk                                 4353      28.8      7044    54.4    1659    15.2    2071    15.1
  Arm                                   2346      15.5      1188    9.2     1103    10.1    1281    9.4
  Leg/foot                              5633      37.2      1786    13.8    1060    9.7     737     5.4
  Other sites                            656       4.3      890     6.9     541     5.0     799     5.8
  **Residential region**                                                                              
  South                                10 875     71.9      9270    71.7    7878    72.1    9537    69.6
  Mid                                   2998      19.8      2525    19.5    2235    20.5    2877    21.0
  North                                 1263       8.3      1138    8.8     810     7.4     1283    9.4
  **Educational level**                                                                               
  ≤ Primary school                       496       3.3      617     4.8     420     3.8     653     4.8
  Secondary school                      5199      34.4      3446    26.6    5678    52.0    5847    42.7
  Some college                          4545      30.0      3271    25.3    3106    28.4    3359    24.5
  ≥ College degree                      4896      32.3      5599    43.3    1719    15.8    3830    28.0
  **Marital status**                                                                                  
  Not married                           6270      41.4      3515    27.2    6981    63.9    4641    33.9
  Married                               8866      58.6      9418    72.8    3942    36.1    9056    66.1
  **Parental status**                                                                                 
  No children                           3875      25.6      2989    23.1    3855    35.3    4226    30.9
  Children                             11 261     74.4      9944    76.9    7068    64.7    9471    69.1
  **Annual income**                                                                                   
  No or missing                         6467      42.7      4118    31.8    8930    81.7    9523    69.5
  \$ 1-9999                             2573      17.0      1639    12.7    801     7.3     1609    11.8
  \$ 10 000--19 999                     1712      11.3      1283    9.9     320     3.0     567     4.1
  \$ 20 000--39 999                     2326      15.4      2166    16.8    462     4.2     782     5.7
  \$ ≥ 40 000                           2058      13.6      3727    28.8    410     3.8     1216    8.9
  **Duration of follow-up (years)**                                                                
  0.0-2.0                               2551      16.9      3050    23.6    2642    24.2    3491    25.5
  2.1-5.0                               2938      19.4      3235    25.0    3019    27.6    3875    28.3
  5.1-10.0                              3044      20.1      2610    20.2    2658    24.3    3427    25.0
  10.1-15.0                             2261      14.9      1577    12.2    1398    12.8    1655    12.1
  15.1-20.0                             1720      11.4      1088    8.4     648     6.0     690     5.0
  20.1-25.0                             1109       7.3      615     4.8     289     2.6     313     2.3
  ≥ 25.1                                1513      10.0      758     5.8     269     2.5     246     1.8
  **Total number**                     15 136      100     12 933   100    10 923   100    13 697   100
  No subsequent cancer                 13 078     86.4     10 995   85.0    9030    82.7    9978    72.9
  Any subsequent cancer                 2058      13.6      1938    15.0    1893    17.3    3719    27.1

The *Norwegian Population Register,* the *Norwegian Education Register* and the *Norwegian Directorate of Taxes* provided information for the cases as well as the general population on individual level characteristics such as date of birth, emigration and death, residential region, attained educational level (1960, 1970, and yearly from 1980 onwards), income (annual from 1966 onwards), parity, and marital status. The data were linked through unique personal identification numbers assigned to every individual residing in Norway from 1960 onwards. Permission to match the data was provided by the National Data Inspectorate in Norway after ethical review of this study by the Norwegian Board of Medical Ethics.

For our study, we obtained individual-level data on all residents during the period 1955--2008 (N = 5.3 million). We used all skin cancer cases and a 20% random sample of the entire population for comparison (N = 1.1 million). Follow-up for skin cancer cases began on the date of diagnosis. For the general population, follow-up began either at age 20 or age in 1955 if greater than 20 at that time. Age and calendar period were included as time-varying covariates, 20--39, 40--59 and ≥ 60 years and 1955--64, 1965--74, 1975--84, 1985--94, 1995--2004 and 2005 and above, respectively. As the majority of Norwegians have completed their education by age 25 and having children by age 35 for the time period under consideration, we used educational level and parental status at end of follow-up in our models. For residential region, marital status and income, we modeled status at the start of follow-up. The average follow-up time was 10.1 years for skin cancer survivors, and 30.6 years for the general population.

We examined the associations between an initial skin cancer and new primary cancers of the skin as well as mouth/pharynx, lung, breast, prostate, thyroid, leukemia and lymphomas, which are the sites with the most evidence of an association in earlier studies \[[@B10]-[@B12],[@B14]-[@B16],[@B19],[@B21],[@B23],[@B25]-[@B30]\]. Exploratory analyses were also undertaken to examine the risk of second cancer at other common sites.

We examined the risk of second cancers by age at diagnosis because young age at onset of the initial cancer may indicate a genetic predisposition. We examined residence by latitude (South, Mid and North, as previously described \[[@B40]\]) because the association between skin cancer and subsequent malignancies is hypothesized to be strongest further from the equator \[[@B21]\]. To account for detection bias attributable to increased attention to cancer symptoms after a skin cancer diagnosis, we also examined the short- and long-term risks of subsequent cancer after diagnosis of a primary skin cancer.

We obtained information on parental cancer diagnoses for the skin cancer survivors who had identified parents (i.e. were alive in 1960). Overall, we were able to link 60% of the skin cancer survivors with their mother and 55% with their father. In general, the linkage rate decreased with increasing age at diagnosis, and we thus performed analyses stratified by year of birth (all, birth year \> 1930 and birth year \> 1950).

Statistical analyses
--------------------

Three types of analyses were conducted. First, we used standardized incidence ratios (SIR) to compare rates of subsequent malignancies in skin cancer survivors with rates of first primary cancer in subgroups of the general population of comparable age, sex and calendar time. The person-years at risk and the observed number of cancer cases were counted by sex within 5-year age groups (20--24, ..., 80--84, 85+), and 5-year calendar periods (1955--59, ..., 2000--04), except for the last period which ran from 2005--08. The expected number of cancer cases was calculated by multiplying the number of person-years in each age group and calendar period in the skin cancer cohort by the corresponding cancer rates in the general Norwegian population. The 95% confidence interval (CI) for the SIR was based on the assumption that the observed number of cases was Poisson-distributed and the expected number was non-stochastic. The analyses were performed using Stata 12 \[[@B41]\].

Second, a discrete-time logistic regression model was used to assess the importance of individual-level risk factors for the risk of a new primary cancer after skin cancer versus a first primary malignancy. Series of twelve-month observations were created for each individual. Individuals were followed from start of follow-up to a first primary malignancy (in a 20% random selection of the general population) or a subsequent malignancy (in skin cancer survivors). Individuals were followed to 2008, unless death, emigration or a malignancy occurred before this time. The follow-up time was categorized as 0--2 years, 3--5 years, 6--10 years, 11--15 years, 16--20 years, 21--25 years or more than 25 years. Categorizations of the covariates are shown in Table  [2](#T2){ref-type="table"}. Interaction terms between a primary skin cancer diagnosis and the various sociodemographic features were included to assess possible effect modification. Based on these results, stratified analyses were undertaken on variables for which effect modification appeared to be present.

###### 

Odds ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression model, comparing the risk of a first cancer in the general population with that of a second cancer in skin cancer survivors

                                        **CMM**              **SCC**                            
  ------------------------------- ------------------- --------------------- ------------------- --------------------
  **Primary skin cancer**                                                                                 
   No                              143 978/31.0 mill        1.00 ref         144 179/31.0 mill        1.00 ref
   Yes                               3662/288 823       1.53 (1.48,1.59)       5612/175 641       2.30 (2.22,2.37)
  **Sex**                                                                                                 
   Female                          72 768/15.8 mill         1.00 ref         72 319/15.7 mill         1.00 ref
   Male                            75 206/15.4 mill     1.28 (1.26,1.29)     77 472/15.4 mill     1.31 (1.29,1.32)
  **Age**^**2**^                                                                                          
   20-40 years                      6447/12.0 mill          1.00 ref          6509/12.0 mill          1.00 ref
   40-59 years                     30 795/10.6 mill     5.37 (5.22,5.52)     30 241/10.5 mill     5.28 (5.14,5.43)
   ≥ 60 years                      110 732/8.6 mill    20.58 (20.04,21.14)   113 041/8.6 mill    20.34 (19.80,20.9)
  **Residential region**^**3**^                                                                           
   North                            21 277/6.0 mill         1.00 ref          21 323/6.0 mill         1.00 ref
   Mid                              34 586/7.2 mill     1.30 (1.27,1.32)      34878/7.2 mill      1.30 (1.28,1.32)
   South                           92 111/18.0 mill     1.33 (1.31,1.35)     93 590/17.9 mill     1.35 (1.33,1.37)
  **Calendar period**^**2**^                                                                              
   \< 1965                           8477/4.3 mill          1.00 ref           8354/4.3 mill          1.00 ref
   1965-1974                        20 484/5.4 mill     2.54 (2.47,2.61)      20 867/5.4 mill     2.62 (2.56,2.6)
   1975-1984                        27 276/5.9 mill     3.63 (3.54,3.73)      27 573/5.9 mill     3.73 (3.63,3.83)
   1985-1994                        33 071/6.3 mill     4.28 (4.17,4.40)      33 817/6.3 mill     4.45 (4.34,4.57)
   1995-2004                        40 142/6.6 mill     5.33 (5.19,5.47)      40 241/6.6 mill     5.41 (5.27,5.56)
   ≥ 2005                           18 524/2.7 mill     5.99 (5.82,6.17)      18 939/2.6 mill     6.22 (6.04,6.40)
  **Educational level**^**4**^                                                                            
   ≤ Primary school                 15 926/1.9 mill         1.00 ref          16 141/1.9 mill         1.00 ref
   Secondary school                67 042/11.8 mill     0.32 (0.31,0.33)     67 915/11.8 mill     0.32 (0.31,0.33)
   Some college                     35 646/7.0 mill     0.30 (0.29,0.31)      36 079/7.0 mill     0.30 (0.29,0.30)
   ≥ College degree                29 360/10.5 mill     0.30 (0.29,0.31)     29 656/10.4 mill     0.30 (0.30,0.31)
  **Marital status**^**3**^                                                                               
   Not married                     47 085/15.7 mill         1.00 ref         47 881/15.7 mill         1.00 ref
   Married                         100 889/15.5 mill    1.25 (1.24,1.27)     101 910/15.4 mill    1.27 (1.25,1.28)
  **Parental status**^**4**^                                                                              
   No children                     138 424/28.9 mill        1.00 ref         139 451/28.9 mill        1.00 ref
   Children                          9550/2.3 mill      0.95 (0.93,0.97)      10 340/2.2 mill     0.96 (0.94,0.98)
  **Income (annual)**^**3**^                                                                              
   \$ 0^5^                          60 395/9.1 mill         1.00 ref          62 871/9.1 mill         1.00 ref
   \$ 80--9 999                    40 528/10.7 mill     0.92 (0.90,0.93)     40 556/10.7 mill     0.91 (0.90,0.92)
   \$ 10 000--19 999                34 425/8.7 mill     0.80 (0.79,0.82)      34 394/8.7 mill     0.80 (0.78,0.80)
   \$ 20 000--39 999                11 582/2.6 mill     0.78 (0.77,0.80)      11 140/2.5 mill     0.76 (0.74,0.78)
   \$ ≥ 40 000                       1044/153 034       0.82 (0.77,0.87)        830/122 013       0.78 (0.73,0.84)

^1^Number of events (new cancers) per person-year during follow-up. ^2^Time-varying covariates (yearly). ^3^At start of follow-up. ^4^At end of follow-up. ^5^Includes also those with missing income data.

Third, internal analyses were undertaken to examine whether cancer-related and sociodemographic factors influence the risk of subsequent malignancies within the cohort of skin cancer survivors. The analyses explored the possible impact of the anatomic site of the primary skin cancer and history of parental cancer. All the discrete-time models were run using the PROC LOGISTIC procedure in SAS 9.2 \[[@B42]\]. Time to subsequent malignancies in men and women was explored using Kaplan-Meier plots, separately for CMM (Figure  [1](#F1){ref-type="fig"}A) and SCC (Figure  [1](#F1){ref-type="fig"}B) survivors, using Stata 12 \[[@B41]\]. The statistical significance level was set at 5%.

![Kaplan-Meier plots of the timing of a second malignancy for men and women after a primary diagnosis of cutaneous malignant melanoma (A) and a primary diagnosis of cutaneous squamous cell carcinoma (B).](1471-2407-14-210-1){#F1}

Results
=======

Overall, 3996 and 5612 subsequent cancers occurred, respectively, among CMM and SCC survivors during follow-up. The characteristics of individuals diagnosed with skin cancer are displayed in Table  [1](#T1){ref-type="table"}. CMM patients were diagnosed at an earlier age, were better educated, had higher incomes, were more frequently married and had children than SCC patients.

Standard incidence ratios (SIR)
-------------------------------

We found 50% and 90% increases in the risks of subsequent cancer after an initial CMM and a SCC diagnosis, respectively (Tables  [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). The strongest risks were observed for subsequent skin cancers, and in particular for skin cancers of the same histology as the index cancer. Increased risks were also observed for several non-skin cancers (thyroid, breast, prostate, leukemia and lymphomas) after both types of skin cancer. After CMM, a 30% increase in risk of central nervous system (CNS) tumors was observed and in men we observed a decreased risk of lung cancer. After SCC, more than a threefold and a sixfold risk increase was observed for mouth/pharynx and salivary gland tumors respectively, as well as a nearly 50% risk increase for lung cancer. Further, the risks of pancreatic and colon cancer were significantly elevated in both sexes, but in women we found a decreased risk of cancers of urinary organs.

###### 

Standard incidence ratios (SIR) with 95% confidence intervals (CI) for a second malignancy by cancer site in men and women with a history of cutaneous malignant melanoma (CMM), adjusted for age and calendar period

                                **Women (N = 15 184**^**1**^**)**   **Men (N = 12 972**^**1**^**)**         
  ----------- ---------------- ----------------------------------- --------------------------------- ------ ------------------
  C00-14      Mouth, pharynx                   14                          0.77 (0.46,1.30)            33    1.11 (0.79,1.56)
  C18         Colon                            163                         1.02 (0.88,1.19)           134    1.16 (0.98,1.37)
  C19-21      Rectum                           57                          0.87 (0.67,1.13)            62    0.93 (0.72,1.19)
  C25         Pancreas                         46                          1.00 (0.76,1.33)            39    1.06 (0.77,1.45)
  C33,34,38   Lung                             109                         1.12 (0.93,1.35)           119    0.72 (0.60,0.87)
  C50         Breast                           377                         1.24 (1.12,1.37)            \-           \-
  C50-58      Female organs                    588                         1.18 (1.09,1.28)            \-           \-
  C61         Prostate                         \-                                 \-                  445    1.26 (1.15,1.38)
  C64-68      Urinary organs                   68                          0.93 (0.73,1.18)           139    0.99 (0.84,1.17)
  C70-72      CNS^4^                           70                          1.39 (1.09,1.75)            41    1.31 (0.98,1.78)
  C73         Thyroid                          19                          1.27 (0.81,1.99)            13    2.78 (1.61,4.80)
  C81-85      Lymphoma                         56                          1.29 (0.99,1.68)            60    1.56 (1.20,1.99)
  C91-95      Leukemia                         72                          1.28 (1.01,1.60)            64    1.22 (0.87,1.43)
  C00-96^5^   Other sites                      169                         1.15 (0.99,1.34)           176    1.07 (0.92,1.24)
  C43         CMM                              438                         7.59 (6.91,8.33)           411    9.44 (8.57,10.4)
  C44         SCC                              197                         3.12 (2.71,3.59)           204    3.11 (2.71,3.56)
  C00-96      All sites                       2066                         1.52 (1.46,1.59)           1943   1.49 (1.43,1.60)
  C00-96^6^   All, exc. skin                  1431                         1.16 (1.11,1.23)           1328   1.12 (1.06,1.18)
  C00-96^7^   All, exc. CMM                   1628                         1.26 (1.20,1.32)           1532   1.25 (1.19,1.31)

^1^The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates from the Cancer Registry of Norway. ^2^The cancer sites are not mutually exclusive. ^3^Observed number of cases. ^4^Central nervous system tumors. ^5^Includes ICD-10 codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. ^6^All sites except C43 and C44. ^7^All sites except C43.

###### 

Standard incidence ratios (SIR) and 95% confidence intervals (CI) for a second malignancy by cancer site in men and women with a history of cutaneous squamous cell carcinoma (SCC), adjusted for age and calendar period

                                 **Women (N = 10 965**^**1**^**)**   **Men (N = 13 748**^**1**^**)**         
  ----------- ----------------- ----------------------------------- --------------------------------- ------ ------------------
  C00-14^4^   Mouth, pharynx                    38                          3.03 (2.20,4.16)           114    3.23 (2.69,3.87)
  C07-08      Salivary glands                   11                          6.69 (3.71,12.1)            17    6.19 (3.85,9.95)
  C18         Colon                             176                         1.25 (1.08,1.45)           197    1.09 (0.95,1.25)
  C19-21      Rectum                            45                          0.86 (0.64,1.14)            96    0.98 (0.80,1.20)
  C25         Pancreas                          45                          1.03 (0.77,1.38)            82    1.39 (1.12,1.73)
  C33,34,38   Lung                              82                          1.46 (1.17,1.81)           303    1.49 (1.32,1.66)
  C50         Breast                            204                         1.15 (1.00,1.32)            \-           \-
  C50-58      Female organs                     320                         1.11 (0.99,1.24)            \-           \-
  C61         Prostate                          \-                                 \-                  650    1.14 (1.06,1.23)
  C64-68      Urinary organs                    42                          0.69 (0.51,0.94)           222    1.08 (0.94,1.23)
  C70-72      CNS^5^                            17                          0.65 (0.40,1.04)            32    1.10 (0.78,1.56)
  C73         Thyroid                           12                          7.30 (4.15,12.8)            3     0.60 (0.19,1.85)
  C81-85      Lymphoma                          64                          2.14 (1.67,2.74)           113    2.41 (2.00,2.90)
  C91-95      Leukemia                          65                          1.33 (1.04,1.69)           150    1.70 (1.45,1.99)
  C00-96^6^   Other sites                       183                         1.13 (0.98,1.31)           371    1.37 (1.23,1.51)
  C43         CMM                               95                          3.09 (2.52,3.78)           122    2.76 (2.31,3.29)
  C44         SCC                               715                         9.88 (9.18,10,6)           1249   10.1 (9.51,10.6)
  C00-96      All sites                        1898                         1.89 (1.81,1.98)           3725   1.91 (1.84,1.96)
  C00-96^7^   All, exc. skin                   1088                         1.22 (1.15,1.30)           2354   1.33 (1.28,1.39)
  C00-96^8^   All, exc. SCC                    1183                         1.23 (1.16,1.30)           2476   1.31 (1.25,1.36)

^1^The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates from the Cancer Registry of Norway. ^2^The cancer sites are not mutually exclusive. ^3^Observed number of cases. ^4^Includes ICD-10 codes C00-06 and C09-14. ^5^Central nervous system tumors. ^6^Includes ICD-10 codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. ^7^All sites except C43 and C44. ^8^All sites except C44.

Logistic regression models
--------------------------

As several cancer forms are associated with socioeconomic status, site-specific analyses controlling for sociodemographic and -economic risk factors were conducted. Results were fairly similar to those observed in the SIR analyses (Table  [5](#T5){ref-type="table"}), e.g., for the risk of breast cancer after either CMM or SCC. However, the model resulted in higher risk estimates for leukemia, lymphoma and colon cancer after CMM or SCC and for cancers of urinary organs after SCC. For prostate cancer there was a lower estimate after CMM but higher after SCC.

###### 

**Odds ratios (OR) and 95% confidence intervals (CI) of subsequent cancer by cancer site for cohorts with a primary cutaneous malignant melanoma (CMM) or cutaneous squamous cell carcinoma (SCC) relative to that of the general population, adjusted for covariates shown in Table** 2^**1**^

                                 **CMM**       **SCC**                 
  ----------- ----------------- --------- ------------------ --------- -------------------
  C00-14^4^   Oral cavity         2768     0.96 (0.68,1.34)    2876     2.70 (2.19,3.34)
  C07-08      Salivary glands      257     0.62 (0.14,2.74)     291     8.89 (5.29,14.93)
  C18         Colon              13 281    1.28 (1.12,1.46)   13 190    1.62 (1.43,1.82)
  C19-21      Rectum              6696     1.15 (0.93,1.42)    6768     1.10 (0.91,1.33)
  C25         Pancreas            4551     1.14 (0.89,1.45)    4590     1.56 (1.27,1.91)
  C33,34,38   Lung               12 347    0.72 (0.62,0.84)   12 613    1.23 (1.09,1.36)
  C50         Breast             17 275    1.21 (1.07,1.36)   16 956    1.16 (1.01,1.34)
  C50-58      Female organs      29 775    1.11 (1.02,1.22)   29 349    1.08 (0.96,1.21)
  C61         Prostate           17 398    1.17 (1.02,1.34)   17 797    1.28 (1.14,1.43)
  C64-68      Urinary organs     10 607    1.00 (0.85,1.18)   10 787    1.18 (1.03,1.37)
  C70-72      CNS^5^              4348     1.73 (1.39,2.15)    4149     1.07 (0.79,1.44)
  C73         Thyroid             1437     1.75 (1.19,2.56)    1435     1.27 (0.75,2.16)
  C81-85      Lymphoma            4672     1.42 (1.14,1.76)    4678     2.78 (2.33,3.32)
  C91-95      Leukemia            6096     1.63 (1.33,1.99)    6162     2.15 (1.83,2.53)
  C00-96^6^   Other sites        21 969    1.27 (1.13,1.43)   22 373    1.67 (1.51,1.84)
  C43         CMM                 6363     7.99 (7.19,8.88)    5827     3.45 (2.94,4.05)
  C44         SCC                 5382     3.31 (2.86,3.82)    6906     14.4 (13.2,15.7)
  C00-96      All sites          147 974   1.53 (1.48,1.59)   149 791   2.30 (2.22,2.37)
  C00-96^7^   All, exc. skin     136 229   1.16 (1.11,1.21)   137 058   1.51 (1.46,1.57)

^1^The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates from the Cancer Registry of Norway. The number of cases are nevertheless quite similar (CMM: SIR 28 156 vs 28 069, events 4009 vs 3996 and SCC: SIR 24 713 vs 24 620, event 5623 vs 5612). ^2^The cancer sites are mutually exclusive. ^3^Observed number of events in a 20% general population sample and the cohort of skin cancer survivors. ^4^Includes ICD-10 codes C00-06 and C09-14. ^5^Central nervous system tumors. ^6^Includes ICD-10 codes 150--152, 155, 156, 158--161, 164, 178, 179, 192, and 195--199. ^7^All sites except C43 and C44.

Table  [2](#T2){ref-type="table"} shows estimates from a fully saturated discrete-time logistic regression model, comparing the risk of a first cancer in the general population with that of a second cancer in skin cancer survivors. Compared to the general population, the cancer risk was approximately 50% and 130% higher after an initial CMM and SCC, respectively. An increased cancer risk was associated with male sex, older age, lower residential latitude, recent calendar time, primary education, low income and being married.

In the comparison between CMM survivors and the general population, interactions were observed for educational attainment, attained age and calendar period (p~interaction~ \< 0.01). In stratified analyses, the risk of a subsequent cancer was higher for CMM survivors with an education at college or university level (Odds ratio (OR) 1.65, CI 1.57-1.74) than for those with a lower education (OR 1.34, CI 1.26-1.42). Similarly, a CMM diagnosis before the age of 60 significantly increased the risk of a subsequent cancer (OR 2.59, CI 2.41-2.79) compared to those older than 60 years (OR 1.43, CI 1.37-1.50). The interaction term between calendar year as a linear variable and CMM diagnosis suggested an increase in risk with more recent calendar time. However, splitting the sample at year 1990 did not identify appreciable differences (≤ 1990: OR 1.57, CI 1.50-1.64 vs. \> 1990: OR 1.64, CI 1.52-1.77).

For SCC survivors in comparison to the general population, interactions were found for parental status, educational attainment, attained age and calendar period (p~interaction~ \< 0.01). Risk for a subsequent cancer was higher for SCC survivors with at least one child (OR 2.64, CI 2.48-2.80) compared to those without children (OR 2.26, CI 2.15-2.37). Further, a higher risk of subsequent cancer was observed for SCC survivors with an education at college or university level (OR 2.49, CI 2.38-2.62) compared to those with a lower education (OR 1.97, CI 1.89-2.06). SCC diagnosis before the age of 60 was associated with a higher risk of subsequent cancer (OR 5.54, CI 4.88-6.29) compared to those older than 60 years (OR 2.07, CI 2.00-2.15). Risk of subsequent cancer was also higher after 1990 (OR 2.52, CI 2.42-2.62) than prior to this (OR 2.29, CI 2.15-2.42).

### Risk of subsequent cancer among skin cancer survivors

The results for the internal comparisons were quite similar for the two subgroups of skin cancer survivors and they confirmed the findings from the external analyses (Table  [6](#T6){ref-type="table"}). No clear difference in the overall risk of subsequent cancer was found across the anatomical sites of the primary skin cancer, after CMM or SCC (data not shown). This was true for all cancer sites, skin included.

###### 

Odd ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression model examining the risk for a subsequent cancer diagnosis within the cohorts with a primary cutaneous malignant melanoma (CMM) or squamous cell carcinoma (SCC)

                                     **CMM**           **SCC**                      
  ------------------------------- -------------- ------------------- -------------- ------------------
  **Sex**                                                                                    
   Female                          2058/173 679       1.00 ref        1893/81 108        1.00 ref
   Male                            1938/115 144   1.51 (1.41,1.63)    3719/94 533    1.90 (1.79,2.01)
  **Age**^**2**^                                                                             
   \< 40 years                      80/31 862         1.00 ref          19/3020          1.00 ref
   40-59 years                     807/106 669    2.89 (2.29,3.65)    222//17 362    2.28 (1.42,3.66)
   ≥ 60 years                      3109/147 183   6.67 (5.31,8.39)    5371/155 259   4.62 (2.93,7.29)
  **Residential region**^**3**^                                                              
   North                            275/23 927        1.00 ref         419/15 325        1.00 ref
   Mid                              703/54 955    1.09 (0.95,1.26)    1124/37 786    1.09 (0.98,1.23)
   South                           3018/209 941   1.20 (1.06,1.36)    4069/122 530   1.20 (1.08,1.33)
  **Calendar period**^**2**^                                                                 
   \< 1965                            6/2959          1.00 ref          35/4411          1.00 ref
   1965-1974                        71/13 448     3.01 (1.30,6.98)     168/10 542    2.51 (1.73,3.64)
   1975-1984                        276/34 380    4.92 (2.15,11.24)    438/22 580    3.61 (2.50,5.20)
   1985-1994                        913/69 763    7.80 (3.43,17.34)   1281/40 225    6.46 (4.52,9.24)
   1995-2004                       1707/112 983   8.88 (3.91,20.17)   2364/64 765    7.76 (5.44,11.1)
   ≥ 2004                          1023/55 290    10.52 (4.63,23.9)   1326/33 118    8.73 (6.10,12.5)
  **Educational level**^**4**^                                                               
   ≤ Primary                         63/5193          1.00 ref          178/6203         1.00 ref
   Secondary                       1285/85 407    0.80 (0.61,1.04)    2514/82 333    0.60 (0.50,0.71)
   Some college                    1293/85 733    0.79 (0.60,1.05)    1577/46 489    0.60 (0.50,0.72)
   ≥ College degree                1355/112 490   0.80 (0.61,1.05)    1343/40 616    0.61 (0.51,0.74)
  **Marital status**^**3**^                                                                  
   Not married                     1089/84 671        1.00 ref        2161/72 265        1.00 ref
   Married                         2907/204 152   1.02 (0.94,1.10)    3451/103 376   1.01 (0.95,1.08)
  **Parental status**^**4**^                                                                 
   No children                      881/68 530        1.00 ref        1692/56 884        1.00 ref
   Children                        3115/220 293   0.91 (0.84,0.99)    3920/118 757   0.93 (0.87,0.99)
  **Income (annual)**^**3**^                                                                 
   \$ 0^5^                         1586/81 524        1.00 ref        3982/113 773       1.00 ref
   \$ 80--9 999                     679/57 594    0.83 (0.75,0.91)     715/24 518    0.85 (0.78,0.92)
   \$ 10 000--19 999                514/50 340    0.68 (0.61,0.75)     300/12 099    0.76 (0.67,0.85)
   \$ 20 000--39 999                713/57 131    0.75 (0.68,0.82)     334/13 692    0.65 (0.58,0.74)
   \$ ≥ 40 000                      504/42 234    0.65 (0.58,0.73)     281/11 559    0.59 (0.51,0.67)

^1^Number of events (new cancers) per person-year during follow-up. ^2^Time-varying covariates (yearly). ^3^At start of follow-up. ^4^At end of follow-up. ^5^Includes also those with missing income data.

Parental cancer
---------------

The risk for a new primary cancer after an initial CMM was not associated with a history of cancer in their mother (OR 1.05, CI 0.90-1.23), father (OR 0.95, CI 0.81-1.11) or either parent (OR 1.00, CI 0.88-1.13), for individuals born after 1930. When we restricted the analyses to those with complete parental linkage (individuals born after 1950), the respective estimates were elevated; risks of cancer after CMM in individuals with a history of cancer in their mother, father or either parent were 1.39 (CI 1.09-1.78), 1.38 (CI 1.09-1.76) and 1.52 (CI 1.21-1.92) respectively. For SCC survivors, the estimates associated with parental cancer were not significantly elevated in the overall or restricted analyses (data not shown).

Time since first primary cancer
-------------------------------

The risk of subsequent cancer after an initial skin cancer increased with time and the risk excess was greater for men than for women (Figures  [1](#F1){ref-type="fig"}A and B). Whereas the increase appeared almost linear for CMM survivors, it rose in a non-linear manner for SCC survivors.

Discussion
==========

The risk of a new primary cancer was higher after an initial skin cancer compared to the risk of a first primary cancer in the general Norwegian population, using multiple approaches. The highest risk was found for a subsequent skin cancer, but several non-skin cancers were also diagnosed in excess including oral, colon, lung, breast, prostate, urinary organs, CNS, thyroid, leukemia and lymphomas. Many of the associations we observed have been reported previously, but we were able to account for a number of sociodemographic factors, and show that the risks remained elevated. Among skin cancer survivors an elevated risk of subsequent cancer was associated with male sex, older age, lower residential latitude, primary education only, low income and being married and the risk increased over the study period. Having children was associated with a slightly decreased cancer risk. Having a parent with a history of cancer increased the risk for a new primary cancer after CMM if diagnosed before age 60.

Individual risk of skin cancer is determined by UVR and host susceptibility \[[@B43]\]. These are the likely explanations for the increased risk of skin and perhaps lip cancer after a CMM or SCC diagnosis, but medical surveillance after the diagnosis may also be important. However, the reasons why individuals with a history of skin cancer have a higher risk of non-cutaneous malignancies, than those without a skin cancer history, are less obvious.

As in previous reports \[[@B9],[@B10],[@B14]-[@B16],[@B18],[@B19],[@B21]-[@B23],[@B25]-[@B30],[@B36]\], we also observed that a history of skin cancer increased the risk of leukemia and lymphoma. Although the mechanism for such an association is not fully understood, several mechanisms have been suggested. First, UVR impairs the immune system, both locally in the skin and systemically \[[@B44]-[@B46]\]. Moreover, immunodeficiency as a result of the disease itself \[[@B27],[@B47],[@B48]\], genetic factors \[[@B44]\] or previous treatment with radiation or chemotherapy \[[@B49],[@B50]\], are all potentially shared risk factors.

We found a history of SCC to be related to an increased risk of lung and mouth/pharynx cancers which is consistent with several previous observations \[[@B9],[@B12],[@B16],[@B19]-[@B21],[@B23],[@B24],[@B26]-[@B30],[@B51]\]. Although UVR has been suggested to play a role also for these cancer types, similar relationships were not observed after CMM. The most reasonable explanation for the increased risk of lung and oral cancer in SCC survivors may be related to tobacco use, which also has been suggested as a risk factor for SCC \[[@B29],[@B51]\]. Moreover, a primary SCC was associated with an increased risk of cancer in urinary organs that also might be related to tobacco. While we have no information on tobacco use, prior studies that were able to control for tobacco use still observed an increased risk of lung \[[@B20],[@B30]\], oral and kidney cancers \[[@B30]\]. Thus, it is possible that the relationship observed between SCC and cancers of mouth/pharynx, lung, and urinary organs lies elsewhere.

The risk of thyroid cancer was significantly increased, both after an initial CMM (both sexes) and SCC (women only), also consistent with previous findings \[[@B11],[@B21],[@B25]-[@B27],[@B31]\]. Common risk factors such as genetic or environmental exposure have been suggested to explain this association \[[@B25]\]. A cancer diagnosis may also increase future health vigilance, which may result in increased detection of new malignancies. Physical examination for CMM includes lymph node palpation in the thyroid area and we cannot exclude the possibility of such surveillance bias. Unfortunately, our numbers were too small to enable a detailed analysis of the development of thyroid cancer with time from a primary skin cancer diagnosis.

With respect to the elevated risk of CNS tumors, we cannot exclude the possibility that the second primary cancer, reported by the clinicians as a CNS tumor, could in some patients be a metastasis from the primary CMM. As CMM but not SCC is likely to spread to the brain, this may explain why no such association was observed between SCC and risk of CNS tumors.

In line with previous studies \[[@B10],[@B15],[@B21],[@B25],[@B27],[@B33],[@B34],[@B52]\], an initial skin cancer diagnosis was found to be associated with an increased risk of colon, breast and prostate cancer. For breast cancer, the relationship was most pronounced after a primary diagnosis of CMM. Shared hormonal mechanisms for CMM and breast cancer have been proposed, although the epidemiological evidence of the role of hormones in melanoma etiology is inconsistent \[[@B52]\]. All these three cancer forms, as well as skin cancer, are associated with high socioeconomic status, and shared risk factors linked to socioeconomic status may account for the positive relationship, including frequent screening activity \[[@B25],[@B34]\]. For CMM survivors this is somewhat confirmed by the lowering of the risk estimates for breast and prostate cancer once socioeconomic factors were taken into account. In contrast, for SCC survivors, the risk estimates for these three cancers rose when accounting for socioeconomic factors.

Sociodemographic factors
------------------------

Several cancer diseases are strongly associated with socioeconomic resources \[[@B53]\] and socioeconomic factors have been suggested to represent mediators by which environmental risk factors vary within a population. In the present study we observed the highest cancer risk in the lowest educational and income levels, and it is likely that this may be attributed to shared adverse lifestyle factors (i.e. smoking habits, alcohol intake, sun protection, diet). The Norwegian health care system intends to ensure equal health care for all inhabitants, independent of socioeconomic level. Nevertheless, individuals who belong to a lower social class tend to have lower health vigilance and participation in surveys and screening programs to minimize the burden of cancer \[[@B54],[@B55]\]. Therefore, we cannot exclude the possibility that our results, at least partly, might be influenced by such mechanisms.

The high risk observed in the elderly may be due to changed sun exposure habits and increased outdoor activities after retirement \[[@B56]\], but there may also be an effect of an age-related diminished immune response \[[@B57],[@B58]\]. Analyses stratified by age, on the other hand, showed that compared to persons in the general population, the risk of a second primary cancer was greatest for the youngest skin cancer survivors, particularly for SCC survivors. A possible explanation might be a genetic susceptibility to skin cancer, which is associated with young age at diagnosis \[[@B59]\], and such susceptibility may also increase the risk for subsequent cancers. Further, the stronger effect of young age seen for SCC survivors may be due to the different patterns of UVR exposure associated with the two skin cancer types (intermittent/accumulated) and to behavior after diagnosis. A CMM diagnosis may, because of its lethal potential, lead to a more sun-protective behavior compared to a SCC diagnosis.

Moreover, steep increases in skin cancer rates over time has been suggested to reflect increased UVR doses \[[@B56]\], and this may in part explain the observed increase of subsequent cancers by calendar time.

The status of being married was associated with an increased risk of subsequent cancer after skin cancer, while having children slightly decreased the risk. Having a family influences the lifestyle in several ways, as they may help ensure more optimal medical surveillance as well as reinforce better health behaviors after diagnosis (i.e. smoking habits, alcohol intake, sun protection, diet, screening attendance) \[[@B60]\], which may cause these relationships.

Parental cancer
---------------

Young age at onset of the initial cancer may be an indication of a genetic predisposition \[[@B61]\]. Contrary to previously reported work \[[@B21],[@B62],[@B63]\], having a parent with cancer did not generally increase the risk of being diagnosed with a subsequent malignancy. However, analyses restricted to individuals born after 1950, showed a near 50% increase in risk when either parent had a history of cancer. Disentangling the effect of age and parental cancer is, however, not possible due to data limitations.

Time since first primary cancer
-------------------------------

An increased health awareness or close follow-up by the health care personnel may result in earlier diagnoses of new cancers in CMM and SCC survivors compared to that of the general cancer-free population \[[@B15],[@B55]\]. Nevertheless, it is unlikely that this can fully explain the observed elevated cancer risk. Higher risk was observed in men than in women, and due to gender difference in health vigilance, we would expect the opposite as women more often interact with health care personnel \[[@B64]\]. The nonlinear increase for SCC survivors may help explain why the interaction terms between a skin cancer diagnosis and calendar year were statistically significant whereas the stratified analyses with a cut-point set arbitrarily in 1990 yielded overlapping confidence intervals for CMM, but not for SCC.

Vitamin D
---------

UVR promotes vitamin D synthesis and vitamin D is demonstrated to regulate several genes involved in cancer processes and is hypothesized to inhibit cancer development \[[@B38]\]. Inverse relationships between a history of skin cancer, as a proxy of high vitamin D levels, and risk of subsequent cancers support this hypothesis \[[@B31],[@B32],[@B34]-[@B37]\], but the vitamin D hypothesis is not supported by the large number of studies that report increased risks of second primary cancers after skin cancer \[[@B9]-[@B30],[@B33]\], and neither by the present results. We found the highest risk of subsequent cancer in the South region, which has the highest UVR dose in Norway. Recently, a study including four cohorts from different regions of Norway observed a slightly higher mean level of serum vitamin D in the cohort comprising residents from the southern part of the country \[[@B65]\]. Therefore, low levels of vitamin D might not explain our findings, although we cannot exclude the possibility that individuals with a history of skin cancer have insufficient vitamin D-levels due to changed sun-exposure habits after diagnosis. Results from a Danish study, however, counters this hypothesis as it demonstrates that previous CMM patients not are more cautious sun bathers \[[@B66]\]. We can also not exclude that other effects of UVR exposure, such as immunodeficiency, may play a role.

Limitations and strengths
-------------------------

The study has several obvious strengths including the long time-span, covering more than 50 years of follow-up, and the large study population, covering the entire Norwegian population. Several cancers were diagnosed in excess, but the highest risk was found for a subsequent skin cancer, particularly of similar type. General practitioners and dermatologists interacting with skin cancer survivors should be aware of this in their surveillance and follow-up.

Individual-level information on some potential confounding variables was available and was found to influence the risk estimates. Less adjusted models are thus likely to over- or underestimate the real risk increase in skin cancer survivors, depending on the direction of the influence of excluded variables. A limitation of the study is the lack of information on parental cancer in older skin cancer survivors. Further, the use of a 20% sample resulted in larger standard errors and thus wider confidence intervals than would have been obtained if we had included the whole population. This is particularly relevant for the site-specific analyses of less common cancer forms, but nevertheless unlikely to have impacted our estimated significantly. Another limitation is the lack of behavioral risk factors such as smoking habits, sun exposure habits, body mass index (BMI), physical activity etc., which would have given more direct information on behavioral changes that may minimize the risk for a second cancer. Lastly, as we chose to primarily focus on socioeconomic factors at time of diagnosis, we are unable to account for changes in these over the life course. Such analyses would shed light on the relevance of developments in socioeconomic characteristics that have taken place in Norway as well as in other industrialized countries over the last 50 years. Nonetheless, there is little reason to believe that the development has been much different for skin cancer survivors compared to the general population given that we adjusted for age, calendar period and follow-up time.

Conclusions
===========

Heightened public awareness may be important to prevent subsequent cancers in skin cancer survivors as the skin cancer incidence rates continue to rise. Of particular relevance to general practitioners and dermatologists dealing with skin cancer survivors, is the need for enhanced surveillance for a new skin cancer. Further, our results provide information on shared risk factors for first and later cancers that may help in identifying individuals at high risk for subsequent cancers, and for whom particular attention ought to be directed.
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